Historically, it has been difficult to protect babies and young children from RSV, but in 2023, the Centers for Disease Control and Prevention (CDC) recommended the use of a monoclonal antibody preparation, called nirsevimab (Beyfortus™), to protect the most susceptible infants against RSV. In this video, Dr. Paul Offit, Director of the Vaccine Education Center, discusses this new product as well as its effectiveness in clinical trials, who should receive it and when.

To learn more about vaccines, please visit http://vaccine.chop.edu.